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Chemical synapses are specialized sites of the communica-
tion between neurons where information is processed and
integrated. Electron microscopy has allowed morphological
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Abstract
SynArfGEF, also known as BRAG3 or IQSEC3, is a member
of the brefeldin A-resistant Arf-GEF/IQSEC family and was
originally identified by screening for mRNA species associated
with the post-synaptic density fraction. In this study, we
demonstrate that synArfGEF activates Arf6, using Arf pull
down and transferrin incorporation assays. Immunohisto-
chemical analysis reveals that synArfGEF is present in
somata and dendrites as puncta in close association with
inhibitory synapses, whereas immunoelectron microscopic
analysis reveals that synArfGEF localizes preferentially at
post-synaptic specializations of symmetric synapses. Using
yeast two-hybrid and pull down assays, we show that syn-
ArfGEF is able to bind utrophin/dystrophin and S-SCAM/
MAGI-2 scaffolding proteins that localize at inhibitory syn-
apses. Double immunostaining reveals that synArfGEF
co-localizes with dystrophin and S-SCAM in cultured hippo-
campal neurons and cerebellar cortex, respectively. Both
b-dystroglycan and S-SCAM were immunoprecipitated from
brain lysates using anti-synArfGEF IgG. Taken together,
these findings suggest that synArfGEF functions as a novel
regulator of Arf6 at inhibitory synapses and associates with
the dystrophin-associated glycoprotein complex and S-SCAM.
Keywords: ADP-ribosylation factor 6, dystrophin, gephyrin,
PDZ domain, post-synaptic density.
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classiﬁcation of synapses into asymmetric and symmetric
types (Gray 1959). Asymmetric synapses, also called Gray’s
type I synapses, are usually excitatory, use glutamate as a
neurotransmitter and are formed on dendritic spines. They
feature a prominent electron-dense thickening at the cyto-
plasmic surface of the post-synaptic membrane called a post-
synaptic density (PSD). Intensive proteomic and molecular
cloning analyses have identiﬁed the molecular components
of excitatory PSDs, which consist of glutamate receptors, cell
adhesion molecules, scaffolding and adaptor proteins, cyto-
skeletal proteins, and signaling molecules including regula-
tors of small GTPases, protein kinases and phosphatases
(Scannevin and Huganir 2000).
By contrast, symmetric synapses, also called Gray’s type II
synapses, are usually inhibitory, use either GABA or glycine
as neurotransmitters and are mainly formed on dendritic
shafts and cell bodies. The PSD at inhibitory synapses is less
electron-dense, having a similar size to the active zone on the
pre-synaptic membrane. Our understanding of the molecular
organization of inhibitory synapses lags behind that of
excitatory PSDs, in part because of the difﬁculty of
puriﬁcation of inhibitory PSDs. Several components such
as gephyrin and dystrophin-associated glycoprotein complex
(DGC) are found to localize selectively at post-synaptic
specializations of inhibitory synapses and are proposed to be
essential for the formation and maintenance of inhibitory
synapses. Gephyrin is a 93-kDa peripheral membrane protein
that was originally co-puriﬁed with glycine receptors (Pfeif-
fer et al. 1982). Several lines of evidence indicate that
gephyrin is essential for the post-synaptic clustering of
glycine receptors (Kirsch et al. 1993; Feng et al. 1998)
and a2- and c2-subunit containing GABAA receptors
(GABAARs) (Essrich et al. 1998). Gephyrin functions as
synaptic scaffold and regulator of receptor trafﬁcking by
interacting with various membrane, signaling, cytoskeletal,
and trafﬁcking proteins (Kneussel and Betz 2000; Fritschy
et al. 2008). Among gephyrin-interacting proteins, colly-
bistin, a guanine nucleotide exchange factor (GEF), was
originally considered to govern synaptic gephyrin localiza-
tion, because collybistin splice variants lacking a src
homology 3 domain can recruit gephyrin from intracellular
aggregates to submembrane clusters in heterologous trans-
fection systems (Kins et al. 2000; Harvey et al. 2004).
However, most isoforms in vivo harbor an Src homology 3
domain, which mediates activation of collybistin-mediated
gephyrin clustering by neuroligin 2 (Poulopoulos et al.
2009). Curiously, studies with collybistin-deﬁcient mice have
revealed that collybistin is only essential for gephyrin-
dependent clustering of speciﬁc subsets of GABAARs in the
hippocampus and amygdala (Papadopoulos et al. 2007),
suggesting that other clustering mechanisms must operate at
inhibitory synapses. On the other hand, the DGC is a large
multiprotein complex that links the extracellular matrix to
the cytoskeleton. Several components of the DGC, including
a- and b-dystroglycan, dystrophin, and b-dystrobrevin were
shown to selectively localize to inhibitory synapses on
neuronal somata and dendrites (Knuesel et al. 1999; Brunig
et al. 2002; Levi et al. 2002; Grady et al. 2006). A study
with dystrophin mutant mdx mice also demonstrated that a
lack of dystrophin reduced the clustering of GABAAR a1
and a2 subunits in the hippocampus and cerebellum
(Knuesel et al. 1999), suggesting that gephyrin-independent
mechanisms also regulate the clustering of GABAAR a1 and
a2 subunits.
SynArfGEF(Po), named as a potential synaptic guanine
nucleotide exchange factor (GEF) for the ADP ribosylation
factor (Arf) family of small GTPases, was originally
identiﬁed by screening for mRNA species associated with
the PSD fraction (Inaba et al. 2004). SynArfGEF(Po)
contains an N-terminal coiled-coil motif, a calmodulin-
binding IQ-like motif, central Sec7 domain and pleckstrin
homology domain and a C-terminal type I PSD-95/Disc
large/Zonula occludens 1 (PDZ)-binding motif (Inaba et al.
2004). All Arf-GEFs contain a Sec7 domain, an approxi-
mately 200-amino acid protein module that is critical for the
catalysis of GDP-GTP exchange on Arf GTPases. Syn-
ArfGEF(Po) belongs to the brefeldin A-resistant Arf-GEF
(BRAG)/IQSEC subfamily of Arf-GEFs based on the
phylogenic classiﬁcation of Sec7 domains (Cox et al.
2004). The Arf family comprises six structurally related
members (Arf1-6) that play an essential role in membrane
trafﬁcking and cytoskeletal rearrangements (D’Souza-Scho-
rey and Chavrier 2006). Among six Arf members, Arf6 is the
most divergent in terms of structure, localizes at plasma
membrane and endosomes, and regulates recycling of the
plasma membrane and peripheral actin cytoskeleton. In
neurons, Arf6 is implicated in the formation and maintenance
of dendritic spines (Choi et al. 2006), the branching of axons
and dendrites (Hernandez-Deviez et al. 2002, 2004), exocy-
tosis and endocytosis of synaptic vesicles (Vitale et al. 2002;
Krauss et al. 2003) and receptor internalization (Delaney
et al. 2002; Krauss et al. 2003; Claing 2004; Houndolo et al.
2005). SynArfGEF(Po) mRNA is expressed widely in the rat
brain and localized at dendrites as well as cell bodies,
suggesting activity-dependent local translation (Inaba et al.
2004). Although synArfGEF(Po) protein shows a punctate
appearance in cell bodies and dendrites of cultured neurons,
its subcellular localization has not been characterized in
detail to date.
To obtain a better understanding of the functional
signiﬁcance of synArfGEF(Po), we ﬁrst demonstrated its
ability to activate Arf6 and therefore renamed it synArfGEF.
Next, we examined the immunohistochemical localization
of synArfGEF in the mouse brain. Intriguingly, synArfGEF
exhibited somatodendritic localization with a high selectivity
for post-synaptic specializations of inhibitory synapses. We
further demonstrated the ability of synArfGEF to interact
with utrophin/dystrophin and synaptic scaffolding molecule
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(S-SCAM) by yeast two-hybrid and pull down assays. These
ﬁndings indicate that synArfGEF is a novel signaling
component at inhibitory post-synaptic sites.
Materials and methods
All animal protocols were approved by the Animal Exper-
imentation and Ethics Committee of the Kitasato University
School of Medicine and followed the guidelines of the
National Institutes of Health.
Vectors
Mammalian expression vectors for synArfGEF (pCAGGS-FLAG-
synArfGEF) and GEP100/BRAG2 (pCAGGS-FLAG-GEP100) were
made by amplifying the coding regions of rat synArfGEF and mouse
GEP100 using PCR with primers containing EcoRI restriction sites
(underlined) as follows: sense, 5¢-GAATTCATGGAGAGCCTGC
TGGAGAACCCGG-3¢ and antisense, 5¢-GAATTCCTACACCAGG
CTCCTGGAGCCACTG-3¢ for synArfGEF; sense, 5¢-GAATTCAT
GCTAGAACGCAAGTATGGGGGAC-3¢ and antisense, 5¢-GAAT
TCTTAGGAGCACAGCACTGGAGGCTG-3¢ for GEP100. After
subcloning into pGEM-T Easy (Promega, Madison, WI, USA), the
cDNA fragments were digested with EcoRI and ligated into the same
restriction site of pCAGGS-FLAG (Niwa et al. 1991; Sakagami et al.
2005). A mammalian expression vector for IQ-ArfGEF/BRAG1,
pCAGGS-FLAG-IQ-ArfGEF/BRAG1, was described previously
(Sakagami et al. 2008). The expression vectors for S-SCAM
[pCIneoMyc S-SCAM (1–1277), (1–301), (295–578), (423–578)]
were described previously (Sumita et al. 2007). The expression
vectors for C-terminally hemagglutinin (HA) epitope-taggedArf1 and
Arf6 in pcDNA3 (Hosaka et al. 1996) were kindly provided by Dr
Kazuhisa Nakayama (Kyoto University). The expression vector for
C-terminally FLAG-tagged Arf6(Q67L) mutant in pCAGGS-neo
(Tanabe et al. 2005) was kindly provided by Dr Masanobu Satake
(Tohoku University).
For Arf pull down assays, the bacterial expression vector
containing the GAT domain of Golgi-localizing, c-adaptin ear
homology domain, Arf-binding protein 1 (GGA1) (Shinotsuka et al.
2002) was kindly provided by Dr Kazuhisa Nakayama (Kyoto
University).
For pMAL-SXN, a bacterial expression vector that has the same
reading frame for the SalI cloning site as that of pGEX4T-2 (GE
Healthcare, Piscataway, NJ, USA), oligonucleotides containing SalI,
XhoI and NotI sites (5¢-AATTGTCGACTCGAGCGGCCGCTGCA-
3¢ and 5¢-GCGGCCGCTCGAGTCGAC-3¢) were annealed and
ligated into the EcoRI and PstI sites of pMAL-c2 (New England
Biolabs, Beverly, MA, USA). To prepare antigens for immunization
and afﬁnity puriﬁcation, the N-terminal region (amino acids 1–293)
of rat synArfGEF, the entire coding region of mouse gephyrin, the
region between PDZ1 and PDZ2 domain of rat S-SCAM (amino
acids 510–570), the region containing 13th and 14th spectrin repeats
of mouse utrophin (amino acids 1761–2101) were ampliﬁed by PCR
with the following primers containing a SalI site (underlined) in
sense primers and a stop codon (small letters) in antisense primers:
5¢-GTCGACCATGGAGAGCCTGCTGGAGAACCCGG-3¢ and 5¢-
ctaTAGGTCAAGGGAGAGTTCGTACTC-3¢ for synArfGEF; GT
CGACCATGGCGACCGAGGGAATGATCCTCAC-3¢ and tcaTAG
CCGTCCAATGACCATGACATC-3¢ for gephyrin; 5¢-GTCGAC
CTGTCGTGGCTACCCTTTGCCCTTTG and 5¢ctaGTGCAA
AGAATGAGGTGGCCGGTCTG-3¢ for S-SCAM; 5¢-GTCGAC
GACCCTGCTGGAACTGTTCAAGCTGC-3¢ and 5¢-ttaCGTTAA
CCAGCAGGTGACCTCATCTAGCC-3¢ for utrophin. After sub-
cloning into pGEM-T Easy, the cDNA fragments were digested
with SalI and NotI and ligated into the same restriction sites of
pGEX4T-2 and pMAL-SXN.
For in vitro binding assays, the C-terminal region of rat
synArfGEF (amino acids 1122–1194) was ampliﬁed by PCR with
primers containing a SalI site (underlined) (5¢-GTCGACCAT
GGAGCCCCTGCTGAGCCAGGCTC-3¢ and 5¢-CTACACCAG
GCTCCTGGAGCCACTG-3¢). After subcloning into pGEM-T
Easy, the cDNA fragment digested with SalI and NotI was ligated
into the same restriction sites of pGEX4T-2. The C-terminal regions
of utrophin corresponding to amino acids 2961–3429, 2691–3058,
and 2691–2843 and dystrophin corresponding to amino acids 2937–
3685 were ampliﬁed by PCR using the primer combinations listed in
Table S1 and ligated into pGEM-T Easy. The inserts were digested
with SalI and NotI and ligated into the same sites of pGEX4T-2.
To construct bait vectors for yeast two-hybrid assays, the
C-terminal regions of synArfGEF shown in Fig. 7b were ampliﬁed
by PCR with primer combinations listed in Table S1 and rat
synArfGEF cDNA as a template. After ligation into pGEM-T Easy,
the inserts were ligated into SalI and NotI sites of pDBLeu
(Invitrogen Corp., Carlsbad, CA, USA) downstream and in frame
with the GAL4 DNA binding domain. For pDBLeu-syn-
ArfGEF(PPPPY ﬁ PPAPA), mutations were introduced in a PY
motif at the C-terminus of synArfGEF using the PrimeSTAR
mutation basal kit (Takara, Tokyo, Japan) with pDBLeu-syn-
ArfGEF(1122–1194) and mutagenesis oligonucleotides (sense,
5¢-CCCCAGCCCCAGCCAACCACCCTCACCAGTT-3¢; antisense,
5¢-GTGGTTGGCTGGGGCTGGGGGTGGGGGCAGTGG-3¢). To
construct prey vectors encoding truncated mutants of utrophin and
dystrophin as shown in Fig 6a, PCR was carried out with the primer
combinations listed in Table S1. After ligation into pGEM-T Easy,
the inserts digested with SalI and NotI were ligated into the same
sites of pPC86. All inserts created in this study were conﬁrmed by
Sanger DNA sequencing.
Arf Pull down assay
The GEF activity of synArfGEF was examined by Arf pull down
assays with GGA1 as described previously (Takatsu et al. 2002;
Sakagami et al. 2006). COS-7 cells were transfected with pcDNA3-
Arf1-HA or pcDNA3-Arf6-HA in the presence or absence of
pCAGGS-FLAG-synArfGEF using Lipofectamine 2000 (Invitro-
gen). Cells were lysed in a buffer containing 50 mM Tris–HCl (pH
7.5), 100 mM NaCl, 2 mM MgCl2, 0.1% sodium dodecyl sulfate
(SDS), 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol
and a cocktail of protease inhibitors (Complete MiniTM, Roche,
Mannheim, Germany). After centrifugation, the supernatants were
incubated with 40 lg of glutathione S-transferase (GST)-GGA1
fusion protein immobilized on glutathione-Sepharose 4B (GE
Healthcare) for 1 h at 4C. The precipitates and lysates were
separated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
and subjected to Western blot analysis with anti-HA (Clontech
Laboratories, Palo Alto, CA, USA) or anti-FLAG antibodies (M2,
Sigma-Aldrich, Inc., St Louis, MO, USA). Immunoreactive bands
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were visualized using a chemiluminescent reagent (ECL-PLUS
Western blotting detection kit, GE Healthcare) and X-ray ﬁlms.
ImageJ (NIH) was used to measure the densities of immunoreactive
bands and statistical analysis was performed using Student’s t-test.
Transferrin incorporation
HeLa cells were transfected with pcDNA3-Arf6(Q67L)-FLAG or
pCAGGS-FLAG-synArfGEF plus pcDNA3-Arf6-HA using Lipo-
fectamine 2000. One day after transfection, cells were serum-starved
for 3 h and incubated with Alexa488-conjugated transferrin (25 lg/
mL) for 20 min at 37C. The cells were then ﬁxed with 4%
paraformaldehyde and immunostained with anti-FLAG IgG. Fluo-
rescent images and intensities were acquired using a confocal
microscope (TCS SP2 AOBS, Leica Microsystems, Wetzlar,
Germany). The ﬂuorescent intensities of cytoplasmic transferrin in
transfected cells were statistically compared with those in non-
transfected cells observed in the same ﬁelds using Scheffe’s test.
Three independent experiments were performed.
Antibodies
The fusion proteins of GST and maltose-binding protein to
synArfGEF, gephyrin, S-SCAM, or utrophin were expressed in
Escherichia coli BL21 (DE3) (Stratagene) in the presence of 1 mM
isopropyl b D-thiogalactopyranoside and puriﬁed with glutathione-
Sepharose 4B and amylose-resin (New England Biolabs), respec-
tively. These GST fusion proteins were then used to immunize
rabbits and guinea pigs. The antibodies were afﬁnity-puriﬁed with
CNBr-activated Sepharose (GE Healthcare) coupled with respective
maltose-binding protein fusion proteins. The speciﬁcity of antibod-
ies for gephyrin, S-SCAM, utrophin was characterized by Western
blot analysis (Figure S1).
Western blot analysis
Mouse brains and COS-7 cells transfected with pCAGGS-FLAG-
synArfGEF, pCAGGS-FLAG-IQ-ArfGEF/BRAG1 or pCAGGS-
FLAG-GEP100 were homogenized with a buffer containing
125 mM Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 1% sodium
deoxycholate, 10% b-mercaptoethanol and a cocktail of protease
inhibitors (Complete MiniTM, Roche) and boiled for 5 min. After
centrifugation, the lysates were separated by SDS–PAGE and
transferred onto polyvinyl diﬂuoride membranes (PVDF-PLUS,
Micron Separations Inc., Westborough, MA, USA). The membranes
were incubated with antibodies against synArfGEF (0.5 lg/mL) or
FLAG (M2, Sigma-Aldrich, 0.5 lg/mL) and subsequently with
peroxidase-conjugated secondary antibodies. Immunoreactive bands
were visualized using a chemiluminescent reagent (ECL-PLUS
Western blotting detection kit, GE Healthcare).
Immunostaining
To conﬁrm the speciﬁcity of antibodies, COS-7 cells were plated
onto 35-mm dishes at the density of 2 · 105 per dish and transfected
with pCAGGS-FLAG-synArfGEF, pCAGGS-FLAG-IQ-ArfGEF/
BRAG1 or pCAGGS-FLAG-GEP100 using Lipofectamine 2000
(Invitrogen). Twenty-four hours after transfection, cell were ﬁxed
with 4% paraformaldehyde and subjected to double immunostaining
with antibodies against synArfGEF and FLAG epitope.
Under deep anesthesia with diethyl ether, C57BL/6N male mice
at postnatal 10–12 weeks transcardially ﬁxed with 4% paraformal-
dehyde plus 0.2% picric acid in 0.1 M phosphate buffer (pH 7.4).
Brains were further immersed with the same ﬁxative overnight,
cryoprotected in 30% sucrose, and sliced at a thickness of 30 lm
with a cryostat. Hippocampal cultures were prepared from 18-day-
old rat embryos at the plating density of 0.6 · 106 per 35-mm dish
as described previously (Sakagami et al. 2005). At 22 days in vitro,
plates were ﬁxed with 2% paraformaldehyde for 5 min.
For immunoperoxidase staining, brain sections were solubilized
in 0.3% Triton X-100 for 30 min, blocked with 5% normal goat
serum for 30 min, and incubated with anti-synArfGEF IgG (1 lg/
mL) overnight. After washing extensively with phosphate-buffered
saline, they were subsequently incubated with peroxidase-conju-
gated anti-rabbit IgG (Histoﬁne Simple Stain MAX PO (R) kit,
Nichirei, Tokyo, Japan) for 1 h at 23C. Immunoreactions were
visualized with 3,3¢-diaminobenzidine tetrahydrochloride chromo-
genic substrate (Liquid DAB and Substrate Chromogen System,
K3468; DAKO, Tokyo, Japan). The pre-embedding silver-enhance-
ment immunogold method was described previously (Sakagami
et al. 2008). Brieﬂy, after incubation with the primary antibody, the
sections were incubated with nanogold-conjugated anti-rabbit IgG
(1 : 100, Nanoprobes Inc., Yaphank, NY, USA), washed with
phosphate-buffered saline, and ﬁxed with glutaraldehyde for
10 min. The gold labeling was intensiﬁed for 3–5 min under a
safety red light using a HQ Silver Enhancement kit (Nanoprobe Inc.)
according to the manufacturer’s instructions. The sections were
treated with 1% osmium tetroxide and 2% uranyl acetate,
dehydrated with ethanol and embedded in epoxy resin. Ultrathin
sections were examined with a JEM-1230 electron microscope
(JEOL Ltd., Tokyo, Japan).
For immunoﬂuorescent staining, samples were incubated with the
combination of rabbit or guinea pig polyclonal anti-synArfGEF IgG
with guinea pig anti-gephyrin IgG, guinea pig anti-PSD-95 IgG
(Fukaya and Watanabe 2000), rabbit anti-IQ-ArfGEF/BRAG1
(Sakagami et al. 2008), rabbit GABAAR a1 subunit IgG (Alamone
Labs, Jerusalem, Israel), anti rabbit anti-vesicular GABA transporter
(VGAT) (Fukudome et al. 2004), guinea pig anti-a-amino-3-hydr-
oxy-5-methyl-4-isoxazolepropionate-type glutamate receptor GluA2
subunit IgG (Yamazaki et al. 2010), guinea pig anti-S-SCAM IgG,
mouse monoclonal anti-glycine receptor a1 subunit IgG (clone
mAb4a, Synaptic Systems, Gottingen, Germany) or anti-dystrophin
IgG (MANDRA-1, Sigma). Immunoreactions were visualized with
the appropriate combination of the following secondary antibodies:
Alexa488-conjugated anti-rabbit IgG, Alexa488- or Alexa594-
conjugated anti-guinea pig IgG, and Alexa594- or Alexa647-
conjugated anti-mouse IgG (Molecular Probes, Inc., Eugene, OR,
USA). Nuclei were counter-stained with 4¢,6-diamidino-2-phenyl-
indole dihydrochloride. Immunoﬂuorescent images were taken with
a confocal microscope (LSM 710, Carl Zeiss, Oberkochen,
Germany) using ·20 and ·63 plan-apochromat objective lens. The
brightness and contrast of the ﬁnal images were adjusted using
Photoshop CS4 software (Adobe Systems, San Jose, CA, USA). In
control experiments, the primary antibody was pre-incubated with
the antigen (10 lM) before immunostaining.
Yeast two-hybrid assay
Yeast two-hybrid screening was performed as described previously
(Sakagami et al. 2007, 2008). Brieﬂy, approximately 2 · 106 clones
of a mouse brain cDNA library were screened using pDBLeu-
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synArfGEF(1122–1194), which encoded the fusion protein of
C-terminal 73 amino acids of rat synArfGEF to the GAL4 DNA-
binding domain, by the ability to grow on selective medium lacking
histidine, leucine and tryptophan supplemented with 10 mM
3-aminotriazole. Positive colonies were further selected by the
b-galactosidase assay and uracil prototrophy. Plasmids were
subjected to the sequencing analysis. To verify the interaction, the
yeast strain MaV203 was co-transformed with the indicated
combination of bait pDBLeu and prey pPC86 vectors shown in
Figs 6 and 7. The interactions were tested by the b-galactosidase
assay and the ability to grow without histidine and uracil.
In vitro binding assay
COS-7 cells were transiently transfected with various plasmid
constructs encoding myc-tagged S-SCAM or FLAG-synArfGEF
and lysed in the lysis buffer consisting of 50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% Nonidet P-40 and a cocktail of protease
inhibitors (Complete MiniTM, Roche). Lysates were incubated with
15 lg of GST, GST-synArfGEF 1122–1194, GST-utrophin 2691–
3429, 2691–3058, 2691–2843, 2937–3685, or GST-dystrophin
2937–3685, immobilized on glutathione-Sepharose 4B for 1 h at
4C. Afterwards, the beads were washed ﬁve times with the lysis
buffer containing 150 mM or 300 mM NaCl and the proteins were
eluted with SDS sample buffer. The cell lysates and eluates were
analyzed by Western blot analysis with anti-myc IgG or anti-FLAG
IgG.
For pull down assays from brain extracts, mouse brains were
homogenized with 10 volumes of the lysis buffer and centrifuged at
12 000 g for 15 min. The supernatant (1 mg) were pre-cleaned with
glutathione-Sepharose 4B for 30 min and incubated with 20 lg of
GST, GST-utrophin 2691–3429, or GST-dystrophin 2937–3685,
which were immobilized on glutathione-Sepharose 4B, for 1 h at
4C. The precipitates were washed with the lysis buffer containing
150 or 300 mM NaCl and subjected to Western blot analysis with
rabbit anti-synArfGEF IgG.
Immunoprecipitation
Immunoprecipitation from brain lysates was performed as described
previously (Sakagami et al. 2008). Brieﬂy, the mouse brain P2
fraction was solubilized with 1% sodium deoxycholate in 50 mM
(a) (b)
(c) (d)
Fig. 1 SynArfGEF activates Arf6. (a) Arf pull down assays. COS-7
cells were transfected with the indicated combination of vectors and
were subjected to Arf pull down assays with the GST-GGA1 fusion
protein. (b) Quantification of the ratio of GTP-bound Arfs to total Arfs.
Note the significant increase in GTP-Arf6 in the presence of FLAG-
synArfGEF (p < 0.01, Student’s t-test). Data are represented as
mean ± SD from three independent transfection samples. (c) Trans-
ferrin incorporation assay. HeLa cells were transfected with FLAG-
synArfGEF plus Arf6-HA or Arf6(Q67L)-FLAG. After serum-starvation,
cells were incubated with Alexa488-transferrin and subjected to
immunostaining. Representative figures show the decreased trans-
ferrin incorporation in cells expressing FLAG-synArfGEF and Arf6-HA
or Arf6(Q67L)-FLAG (arrows) compared with that in non-transfected
cells (arrowheads). Scale bars, 10 lm. (d) Quantification of the fluo-
rescence intensity of intracellular transferrin. Data are represented as
mean ± SEM from three independent experiments. Asterisks indicate
significant difference of fluorescence intensities between transfected
and non-transfected cells (p < 0.01, Scheffe’s test).
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Tris–HCl (pH 9.0) and dialyzed against the binding buffer [0.1%
Triton X-100, 50 mM Tris–HCl (pH 7.4)]. After pre-cleaning with
Protein G-Sepharose 4B, the soluble supernatant (1 mg) was
incubated with 5 lg of anti-synArfGEF IgG or normal rabbit IgG
for 1 h at 4C and with Protein G-sepharose 4B for another 1 h. The
beads were washed ﬁve times with the binding buffer plus 150 mM
NaCl. Proteins were eluted with SDS sample buffer, subjected to
SDS–PAGE and immunoblotted with antibodies against S-SCAM
(M2441, Sigma) or b-dystroglycan (clone 43DAG1/8D5, Nova-
castra Laboratories, Newcastle, UK).
Results
SynArfGEF activates Arf6
Two related proteins in the BRAG/IQSEC family of Arf-
GEFs, IQ-ArfGEF/BRAG1/IQSEC2 and GEP100/BRAG2/
IQSEC1 have previously been shown to activate Arf6
(Someya et al. 2001; Sakagami et al. 2008). To examine
whether synArfGEF/BRAG3/IQSEC3 activates Arf6, we
performed Arf pull down assays with a GST-GGA1 fusion
protein that is capable of binding GTP-bound Arfs of all
classes. COS-7 cells were co-transfected with FLAG-
synArfGEF and Arf1-HA or Arf6-HA. Immobilized GST-
GGA1 pulled down 4.13-fold more GTP-Arf6-HA from the
lysates of COS-7 cells expressing both Arf6-HA and FLAG-
synArfGEF than Arf6-HA alone (p = 0.0092 by Student’s
t-test, Fig. 1a and b). Co-transfection of Arf1-HA and
FLAG-synArfGEF increased both total and GTP-bound
Arf1 to a similar extent and did not change the ratio of
GTP-Arf1 to total Arf1 (Fig. 1a and b). We further examined
the ability of synArfGEF to activate Arf6 in vivo using a
transferrin incorporation assay. Arf6 has been shown to
regulate the endocytosis of transferrin receptor (D’Souza-
Schorey et al. 1995). If synArfGEF activates Arf6 in vivo,
transferrin uptake would be affected by over-expressing
synArfGEF. We therefore examined the incorporation of
transferrin in HeLa cells transfected with FLAG-synArfGEF
and Arf6-HA. In non-transfected cells, transferrin accumu-
lated in the perinuclear region (Fig 1c). By contrast, the
incorporation of transferrin was reduced by 48.7% in cells
transfected with FLAG-synArfGEF and Arf6-HA compared
to non-transfected cells (Fig. 1c and d). This reduction was
comparable with the reduction (31.9%) observed for cells
transfected with the GTP hydrolysis-defective Arf6 mutant,
Arf6(Q67L). Taken together, these ﬁndings suggest that
synArfGEF activates Arf6 in vivo.
Preferential localization of synArfGEF at inhibitory
synapses
We have previously shown that synArfGEF mRNA is
expressed preferentially in the olfactory bulb, cerebral cortex,
hippocampus, brainstem nuclei and cerebellar Purkinje cells
of the adult rat brain (Inaba et al. 2004). In this study, we
produced novel anti-synArfGEF antibodies for use in
immunohistochemistry. Western blot analysis using the
lysates of COS-7 cells transfected with FLAG-tagged BRAG
family members showed that both antibodies raised in rabbit
and guinea pig detected FLAG-synArfGEF, while they did
not cross-react with other BRAG members, FLAG-IQ-
ArfGEF/BRAG1 or GEP100 (Fig. 2). In the mouse brain
lysate, the antibodies gave two immunoreactive bands of 160
and 130 kDa (Fig. 2), suggesting the existence of two
alternatively spliced isoforms as is the case for the other
BRAG/IQSEC family members (Dunphy et al. 2006; Shou-
bridge et al. 2010). Notably, the electrophoretic mobility of
the 160 kDa band was consistent with that of recombinant
FLAG-synArfGEF detected using an anti-FLAG antibody
(Fig. 2). Further to conﬁrm the speciﬁcity, COS-7 cells were
transfected with FLAG-tagged BRAG members and sub-
jected to immunostaining. Again, the antibodies speciﬁcally
detected COS-7 cells transfected with FLAG-synArfGEF
without any immunolabeling in non-transfected cells or cells
transfected with FLAG-IQ-ArfGEF/BRAG1 or GEP100
(Figure S2). Immunoperoxidase staining of mouse brain
sections with rabbit anti-synArfGEF IgG yielded intense
labeling in the olfactory bulb, cerebral cortex, hippocampal
formation, reticular thalamic nucleus, superior and inferior
colliculi, cerebellar cortex and various brainstem nuclei
(Fig. 3a). This immunolabeling pattern was compatible with
the expression pattern of synArfGEF mRNA in the rat brain
described previously (Inaba et al. 2004). In control experi-
ments, the primary antibody pre-absorbed with the antigen
did not show any immunolabeling (Fig. 3b). In addition,
both rabbit and guinea pig antibodies gave an identical
labeling pattern (data not shown). Taken together, all these
Fig. 2 Characterization of anti-synArfGEF antibodies by Western blot
analysis. Lysates from mouse brain and COS-7 cells expressing
FLAG-tagged synArfGEF, IQ-ArfGEF/BRAG1, or GEP100 were sub-
jected to Western blot analysis with rabbit and guinea pig polyclonal
antibodies against synArfGEF or anti-FLAG IgG.
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ﬁndings suggest the immunolabeling observed with these
antibodies is speciﬁc for synArfGEF.
In the hippocampus, synArfGEF immunoreactivity was
widely distributed, with the highest level observed in the
CA3 region (Fig. 3c). SynArfGEF labeling was observed
diffusely in both neuronal somata and dendrites, but not in
nuclei, of pyramidal cells. In addition to this diffuse
cytoplasmic labeling, tiny puncta (< 1 lm in diameter) were
distributed on the surface of the somata and dendrites
(Fig. 3d), consistent with synaptic localization. To examine
whether synArfGEF is associated with excitatory or inhib-
itory synapses, double immunoﬂuorescence staining was
performed with antibodies against synArfGEF and PSD-95,
gephyrin or IQ-ArfGEF/BRAG1 (Fig. 3e–m). Extensive
colocalization was observed between synArfGEF and geph-
yrin along somata and dendritic shafts (Fig. 3e–g), whereas
synArfGEF puncta were rarely co-localized with PSD-95 or
IQ-ArfGEF/BRAG1 (Fig. 3h–m).
In the olfactory bulb, synArfGEF immunoreactivity was
distributed in the mitral cell, external plexiform, and glomer-
ular layers (Fig. 3n). In mitral cells, somata and dendrites were
heavily immunolabeled. Along their dendritic shafts in the
external plexiform layer, synArfGEF labeling was distributed
as puncta largely co-localized with gephyrin (Fig. 3o–q).
In the neocortex, synArfGEF immunoreactivity was
distributed throughout the cortical layers. Pyramidal neurons
in the layer V were intensely immunolabeled in their
somatodendritic compartments without nuclear staining
(a)
(b)
(c)
(d) (e) (f) (g)
(h) (i) (j)
(k) (l) (m)
(n) (o) (r) (s)
(t)
(u)
(p)
(q)
Fig. 3 Immunohistochemical localization of
synArfGEF in the forebrain. (a, b) Sagittal
sections from adult mouse brain were sub-
jected to immunoperoxidase staining with
the rabbit polyclonal anti-synArfGEF IgG (a)
or antibody pre-absorbed with the antigen
(10 lM) (b). Note the complete attenuation
of immunolabeling by pre-incubation with
the antigen. (c) Immunofluorescent locali-
zation of synArfGEF in the adult mouse
hippocampus. (d–m) Immunofluorescent
localization of synArfGEF in the hippocam-
pal CA3 region. Coronal sections were im-
munostained for synArfGEF (e, h, k) and
gephyrin (f), PSD-95 (i), or IQ-ArfGEF/
BRAG1 (l). Note the colocalization of syn-
ArfGEF with gephyrin but not PSD-95 or
IQ-ArfGEF. (n–q) Immunofluorescent
localization of synArfGEF in the olfactory
bulb. Note the colocalization of synArfGEF
(o) and gephyrin (p) in the external plexi-
form layer (EPL). (r–u) Immunofluorescent
localization of synArfGEF in the cerebral
pyramidal neurons. Note the colocalization
of synArfGEF (s) and gephyrin (t). Nuclei
were counter-stained with 4¢,6-diamidino-2-
phenylindole dihydrochloride (DAPI) (blue)
in panles d, n, and r. CA1-3, subfield CA1-3
of Ammon’s horn; Cb, cerebellar cortex;
CP, caudate putamen; Cx, cerebral cortex;
DG, dentate gyrus; Gr, dentate granule cell
layer; Hi, hippocampus; Md, midbrain; Mi,
mitral cell layer; MO, medulla oblongata;
Mo, molecular layer, OB, olfactory bulb; SL,
stratum lucidum; SLM, stratum lacunosum-
moleculare; SO, stratum oriens; SP, stra-
tum pyramidale; SR, stratum radiatum; Th,
thalamus. Scale bars, 1 mm (a); 200 lm
(c); 10 lm (d, n, R); 5 lm (g, j, m, q, u).
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(Fig. 3r). At high magniﬁcation, synArfGEF was found in
ﬁne puncta along the somata and dendrites, which were
largely co-localized with gephyrin (Fig. 3s–u).
In the cerebellar cortex, synArfGEF immunoreactivity was
observed in the somata and dendritic shafts of Purkinje cells,
and the somata of basket cells and stellate cells in the
molecular layer, and the somata of Golgi cells in the granular
layer (Fig. 4a). However, the somata of granule cells were
devoid of immunolabeling for synArfGEF. At high magniﬁ-
cation, tiny immunoreactive puncta were found to be distrib-
uted along Purkinje cell dendrites and co-localized well with
gephyrin (Fig. 4b–d) and GABAAR a1 subunit (Fig. 4e–g)
without overlapping with a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate receptor GluA2 subunit (Fig. 4h–j).
In the spinal cord, synArfGEF immunoreactivity was
distributed in the gray matter. In particular, the somata and
dendrites of ventral motoneurons were heavily immuno-
labeled (Fig. 4k). The immunoreactive puncta along the
somata and dendritic shafts were largely co-localized with
both glycine receptors and gephyrin (Fig. 4k–n). Immuno-
reactive puncta were also closely apposed to VGAT labeling,
forming merged color at the interface (Fig. 4o–q). These
confocal microscopic results suggest that synArfGEF is
preferentially distributed at inhibitory synapses throughout
the central nervous system.
To determine the precise synaptic localization, we per-
formed pre-embedding immunogold electron microscopy in
the external plexiform layer of the olfactory bulb (Fig. 5a),
the molecular layer of the cerebellar cortex (Fig. 5b), and
spinal motoneurons (Fig. 5c). Immunogold particles for
synArfGEF accumulated on or beneath the post-synaptic
membrane of symmetric synapses formed on dendritic shafts
(a) (b)
(e)
(h)
(c)
(f)
(i)
(d)
(g)
(j)
(k) (l)
(m) (n)
(o)
(p)
(q)
Fig. 4 Immunohistochemical localization of
synArfGEF in the cerebellum and spinal
cord. (a–j) Localization of synArfGEF in the
cerebellar cortex (Cb). A sagittal section of
the adult mouse cerebellar cortex (Cb) was
immunostained for synArfGEF (b, e, h) and
gephyrin (c), GABAAR a1 subunit (f), or
GluA2 subunit (i). Note that immunolabeling
of synArfGEF in the cell bodies of Purkinje
cells, basket cells (arrowhead), stellate cells
and Golgi cells (arrows) as well as dendrites
of Purkinje cells in the molecular layer (Mo).
Also note the colocalization of synArfGEF
with gephyrin and GABAAR a1 subunit but
not GluA2 subunit in the molecular layer.
Gr, granular layer; PC, Purkinje cell layer.
(k–q) Localization of synArfGEF in spinal
motoneurons (SM). Coronal sections of the
spinal cord were immunostained for syn-
ArfGEF (k), gephyrin (l) and glycine recep-
tor a subunit (m) or with synArfGEF (o) and
VGAT (p). Note the colocalization of syn-
ArfGEF, gephyrin and glycine receptor a
subunit along the cell body/dendritic shafts
and the close apposition of synArfGEF to
VGAT. Scale bar, 20 lm (a); 5 lm (d, g, j,
n, q).
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and cell bodies. By contrast, no signiﬁcant immunogold
particles were observed at asymmetric synapses on olfactory
mitral cells (Fig. 5a), cerebellar Purkinje cells (Fig. 5b), or
spinal motoneurons (Fig. 5c). These ﬁndings conﬁrm that
synArfGEF localizes exclusively at post-synaptic specializa-
tions of inhibitory synapses.
Interaction of synArfGEF with utrophin/dystrophin
To identify interacting proteins with synArfGEF, we per-
formed yeast two-hybrid screening of a mouse brain cDNA
library, using the C-terminal 73 amino acids of synArfGEF
as bait. We isolated two independent cDNA clones (#5 and
#57) encoding utrophin, a large cytoskeletal protein with
high structural similarity to dystrophin (Fig. 6a). Both clones
encoded an overlapping C-terminal region (amino acids
2698–3429) containing a partial 20th spectrin repeat, the
WWand Zn2+ ﬁnger motifs, and two coiled-coil domains. As
dystrophin was shown to localize at inhibitory synapses and
to regulate the clustering of selected GABAAR subtypes
(Knuesel et al. 1999), we further examined whether the
corresponding C-terminal region of dystrophin (amino acids
2937–3685) could interact with the C-terminus of syn-
ArfGEF. Indeed, yeast expressing dystrophin 2937–3685 and
synArfGEF 1122–1194 exhibited signiﬁcant b-galactosidase
activity and the ability to grow without histidine and uracil
(Fig. 6b), indicating a robust protein-protein interaction.
Next, we determined the region of utrophin responsible for
the interaction with synArfGEF using two-hybrid assays with
synArfGEF bait and various truncated mutants of utrophin as
shown in Fig 6a. Yeast expressing synArfGEF and utrophin
fragments 2691–3429, 2691–3111 and 2691–3058 exhibited
detectable b-galactosidase activity, although the prototrophy
for histidine and uracil was markedly disturbed in yeast
expressing utrophin 2691–3111 and 2691–3058 (Fig. 6b).
The interaction was not detected when utrophin 2691–3058
was further truncated (amino acids 2810–3058, 2691–2843,
or 2810–2843) or the WW motif was deleted (utrophin
fragments 2843–3429, 3061–3429, and 3249–3429)
(Fig. 6a). These ﬁndings suggest that the minimal region of
utrophin required for the interaction corresponds to amino
acids 2691–3058.
The synArfGEF-utrophin interaction was also indepen-
dently veriﬁed using pull down assays. Consistently,
GST-utrophin 2691–3429, 2691–3058 and GST-dystrophin
2937–3685 were capable of efﬁcient pull down of full-
length FLAG-synArfGEF from transfected COS-7 cell
lysates, whereas neither GST-utrophin 2691–2843 nor
GST alone was capable of mediating this interaction
(Fig. 6c). The synArfGEF-utrophin interaction was retained
even when the salt concentration in the washing buffer was
raised to 300 mM, although the interaction between GST-
utrophin 2691–3058 and synArfGEF was decreased
(Fig. 6c). Furthermore, GST-utrophin 2691–3429 and
GST-dystrophin 2937–3685, but not GST alone, efﬁciently
pulled down endogenous synArfGEF from brain extracts
(Fig. 6d).
The C-terminal 73 amino acids of synArfGEF used as bait
contain a proline-rich sequence and type I PDZ-binding
motif. The proline-rich domain is followed by a tyrosine
residue (sequence PPPPY), which forms a known motif for
binding to WW domains – the PY motif (Chen and Sudol
1995; Rentschler et al. 1999) (Fig. 7a). As the minimal
region of utrophin required for robust interactions with
synArfGEF contains a WW motif, we examined whether this
PY motif mediated the synArfGEF–utrophin interaction.
Activation of reporter genes was observed when yeast was
co-transformed with utrophin 2653–3429 and synArfGEF
1122–1194, DC3, 1122–1172, or 1141–1194, all of which
contained the PY motif, although the b-galactosidase activity
was dramatically reduced in the yeast transformed with
(a) (b) (c)
Fig. 5 Subcellular localization of synArfGEF by immunoelectron
microscopy using the silver-enhanced immunogold method. Note the
accumulation of immunogold particles for synArfGEF at post-synaptic
specializations of symmetric synapses of the dendritic shafts of an
olfactory mitral cell in the external plexiform layer (a), a Purkinje cell in
the molecular layer (b), and a spinal motoneuron (c). Note the absence
of immunolabeling at asymmetric synapses (arrows). Scale bars,
200 nm.
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utrophin 2653–3429 and synArfGEF 1122–1172 (Fig. 7b).
The substitution of proline and tyrosine residues in the PY
motif to alanine residues (PPPPY ﬁ PPAPA) disrupted the
interaction between synArfGEF and utrophin (Fig. 7a and b),
suggesting that the PY motif in synArfGEF is critical for this
interaction.
To examine whether synArfGEF and utrophin/dystrophin
co-localize at synapses, cultured hippocampal neurons were
prepared from rat embryos, maintained for 22 days and
immunostained with antibodies against synArfGEF and
dystrophin or utrophin. Dendritic synArfGEF puncta showed
extensive colocalization with dystrophin (Fig. 8b–d). By
contrast, anti-utrophin did not immunolabel hippocampal
neurons (data not shown). Furthermore, synArfGEF-immu-
noreactive puncta were also associated with GABAAR a1
subunit and VGAT but not with PSD-95 (Fig. 8e–m). Taken
together, these ﬁndings suggest that synArfGEF and dystro-
phin form a complex at inhibitory synapses of hippocampal
neurons in vivo, mediated by PY-motif and WW domain
interactions.
Fig. 6 Interaction of synArfGEF with utrophin/dystrophin. (a) Sche-
matic representation of the domain structures of utrophin and dystro-
phin and the protein fragments used in the yeast two-hybrid assays.
(b) Two-hybrid assays. The yeast strain MaV203 was transformed with
the indicated combinations of constructs and plated onto synthetic
complete medium lacking leucine and tryptophan: LT()), or leucine,
tryptophan, histidine and uracil: LTHU()). Interactions were assessed
by b-galactosidase activity (b-gal) and prototrophy for histidine and
uracil. Note the interaction of synArfGEF with utrophin fragments
2653–3429, 2691–3429, 2691–3111, 2691–3058, and dystrophin
fragment 2937–3685. (c, d) Pull down assays. Lysates from COS-7
cells transfected with pCAGGS-FLAG-synArfGEF (c) and mouse
brains (d) were subjected to pull down assays with the indicated GST
fusion proteins that were conjugated with glutathione-Sepharose 4B.
The precipitates were washed with the lysis buffer containing 150 or
300 mM NaCl and subjected to Western blot analysis with anti-FLAG
IgG (c) or anti-synArfGEF IgG (d).
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Interaction of synArfGEF with S-SCAM/MAGI-2
In addition to utrophin, we also isolated several independent
clones encoding the membrane-associated guanylate kinase
with inverted orientation (MAGI) family, which contains six
PDZ domains, two WW domains and one guanylate kinase
domain and comprises of three members, MAGI-1, S-SCAM
(also called MAGI-2), and MAGI-3. S-SCAM was previ-
ously shown to localize at inhibitory synapses and to act as a
molecular bridge between the neurexin-neuroligin complex
and the DGC via direct interactions with two adhesion
molecules at inhibitory synapses, neuroligin-2 and b-dystro-
glycan (Sumita et al. 2007). We therefore examined whether
synArfGEF could interact with S-SCAM using pull down
assays (Fig. 9a). GST-synArfGEF 1122–1194 efﬁciently
pulled down full-length S-SCAM from lysates of transfected
COS-7 cells. We further determined which region of
S-SCAM was responsible for this interaction using various
truncated S-SCAM mutants as shown in Fig. 9a. GST-
synArfGEF 1122–1194 could efﬁciently pull down S-SCAM
295–578 containing two WW domains and the PDZ1
domain, while it could not pull down S-SCAM 1–301 or
573–1277. Although the binding efﬁciency was drastically
reduced, S-SCAM 425–578 containing only PDZ1 domain
retained the ability to bind to GST-synArfGEF 1122–1194
(Fig. 9a), indicating that PDZ1 domain is the minimal
requirement for the interaction with synArfGEF.
To examine whether synArfGEF co-localizes with
S-SCAM at synapses, we performed double immunoﬂuores-
cent staining of the cerebellar cortex (Fig. 9b). In the
molecular layer, both synArfGEF and S-SCAM were
distributed in puncta, although S-SCAM puncta were slightly
larger in size. The anti-synArfGEF IgG labeled 43% of
S-SCAM puncta (n = 202), whereas the anti-S-SCAM IgG
labeled 26% of synArfGEF puncta (n = 335). These ﬁndings
suggest that synArfGEF partially co-localizes with S-SCAM
in the cerebellar molecular layer.
Finally, we performed co-immunoprecipiation experiments
from brain lysates to examine whether synArfGEF forms a
proteins complex with dystrophin and S-SCAM in vivo. The
anti-synArfGEF IgG, but not normal rabbit IgG, efﬁciently
immunoprecipitated S-SCAM from the deoxycholate-solu-
bilized P2 fraction (Fig. 9c). Although we failed to detect
dystrophin or utrophin in the immunoprecipitates (data not
shown), the anti-synArfGEF IgG clearly immunoprecipitated
(a) (b) (c) (d)
(e) (f) (g)
(h) (i) (j)
(k) (l) (m)
Fig. 8 Colocalization of synArfGEF and dystrophin at inhibitory syn-
apses of cultured hippocampal neurons. Cultured hippocampal neu-
rons at 22 DIV were immunostained with anti-synArfGEF (a, b, e, h, k)
and anti-dystrophin (c), GABAAR a1 subunit (f), VGAT (i) or PSD-95 (l)
antibodies. Note the close association of synArfGEF with dystrophin,
GABAAR a1 and VGAT but not with PSD-95. Arrowheads in high-
magnification views (b–d) show the colocalization of endogenous
synArfGEF and dystrophin along dendrites. Scale bars, 10 lm (a);
5 lm (d, g, j, m).
(a)
(b)
Fig. 7 Interaction of synArfGEF with utrophin via a PPPPY motif. (a)
Sequence alignment of the consensus PPPPY motif required for
binding to WW domains, proline-rich sequence of the C-terminal
region of synArfGEF and the mutant (PPPPY ﬁ PPAPA). (b) Two-
hybrid assays. The yeast strain MaV203 was transformed with the
indicated combinations of constructs and plated onto synthetic com-
plete medium lacking leucine and tryptophan: LT()) or leucine, tryp-
tophan, histidine and uracil: LTHU()). Interactions were assessed by
b-galactosidase activity (b-gal) and the ability to grow on LTHU())
medium. Note the disruption of the interaction with utrophin by the
mutation in a PPPPY motif (PPPPY ﬁ PPAPA).
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b-dystroglycan from the deoxycholate-solubilized P2 frac-
tion (Fig. 9c). Taken together, these results suggest that
synArfGEF is likely to be present in the DGC and associate
with S-SCAM at inhibitory synapses.
Discussion
The BRAG/IQSEC family is composed of three members,
IQ-ArfGEF/BRAG1/IQSEC2, GEP100/BRAG2/IQSEC1,
and synArfGEF/BRAG3/IQSEC3, all of which share char-
acteristic domain organization containing an N-terminal
IQ-like motif, a central Sec7 domain and pleckstrin homol-
ogy domain (Table 1). GEP100/BRAG2/IQSEC1, a proto-
typical member of this family, was shown to activate Arf6
in vitro and in vivo (Someya et al. 2001; Morishige et al.
2008). IQ-ArfGEF/BRAG1/IQSEC2 was subsequently
shown to activate Arf6 using pull down assays with GST-
GGA1 (Sakagami et al. 2008). In this study, we have shown
that synArfGEF/BRAG3/IQSEC3 also functions as a GEF
for Arf6 in vivo by using pull down and transferrin
incorporation assays. However, we were unable to conclu-
sively demonstrate the GEF activity of synArfGEF toward
Arf1, because co-transfection of synArfGEF and Arf1
increased total Arf1 in the lysate to the same extent as
GTP-Arf1 pulled down by GST-GGA1. By contrast, Hattori
et al. (2007) have previously shown that KIAA1110,
encoding a human homologue of synArfGEF, exhibits GEF
activity toward Arf1 but not Arf6 using an Arf pull down
assay with the same GST-GGA1. The reasons for this
discrepancy are unknown at present. However, as KIAA1110
is a partial 770 amino acid protein corresponding to amino
acids 439–1194 of rat synArfGEF, the complete structure of
synArfGEF may be required for GEF activity toward Arf6.
The PSD of excitatory synapses is known to contain a
diverse array of GEFs and GTPase-activating proteins
(GAPs) for small GTPases: Ras-GAP (synGAP) (Chen et al.
1998), Arf-GEFs (BRAG1, BRAG2b) (Murphy et al. 2006;
Dosemeci et al. 2007; Sakagami et al. 2008), Arf-GAPs
(GIT1 and PIKE-L) (Peng et al. 2004), Rac-GEF (Kalirin)
(Penzes et al. 2000), Rap-GEF (cAMP-GEFII/Epac2) (Peng
(a)
(b) (c)
Fig. 9 Interaction of synArfGEF with S-SCAM. (a) Pull down assays.
COS-7 cells were transfected with the S-SCAM constructs shown in
the left panel and subjected to pull down assays with GST-synArfGEF
1122–1194. Note the interaction of GST-synArfGEF 1122–1194 with
S-SCAM fragments 1–1277, 295–578, and 425–578. (b) Immunoflu-
orescent staining of the cerebellar molecular layer, showing the partial
colocalization of synArfGEF and S-SCAM (arrows). (c) Co-immuno-
precipitation assays. Deoxycholate-solubilized P2 fractions were
immunoprecipitated with anti-synArfGEF IgG or normal rabbit IgG and
subjected to Western blot analysis with antibodies against S-SCAM
and b-dystroglycan (b-DG). Note the co-immunoprecipitation of
S-SCAM and b-dystroglycan with synArfGEF from brain lysates.
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et al. 2004), and Rap-GAP (SPAR) (Pak et al. 2001). These
regulatory proteins for small GTPases are proposed to
modulate synaptic transmission by regulating the formation
and maintenance of dendritic spines and synapses through
the actin cytoskeleton reorganization (Penzes et al. 2001;
Zhang et al. 2003, 2005; Vazquez et al. 2004; Woolfrey
et al. 2009). Among the BRAG family, IQ-ArfGEF/BRAG1/
IQSEC2 was shown to localize at the PSD of excitatory
synapses and form a protein complex with NMDA-type
glutamate receptors, possibly via an interaction with PSD-95
(Murphy et al. 2006; Dosemeci et al. 2007; Sakagami et al.
2008) and insulin receptor tyrosine kinase substrate of
53 kDa (IRSp53) (Sanda et al. 2009) (Table 1). Mutations in
IQSEC2 have recently been reported in patients with non-
syndromic X chromosome-linked intellectual disability
(Shoubridge et al. 2010). Interestingly, mutations in three
of four separate families with non-syndromic X chromo-
some-linked intellectual disability lead to amino acid substi-
tutions in the Sec7 domain and consequent reduction of the
GEF activity toward Arf6, suggesting the functional signif-
icance of IQSEC2-Arf6 pathway in neuronal morphology
or synaptic plasticity (Shoubridge et al. 2010). In sharp
contrast, we show that synArfGEF localizes preferentially at
post-synaptic specializations of inhibitory synapses. This
major ﬁnding was conﬁrmed by several independent lines of
immunohistochemical evidence. To our knowledge, the only
known regulator of small GTPases found at inhibitory post-
synaptic specializations is collybistin, a GEF for Cdc42,
which was identiﬁed as an interacting protein for gephyrin by
yeast two-hybrid screening (Kins et al. 2000). Thus, syn-
ArfGEF is listed as the second known regulator of GTPase
that shows preferential localization at post-synaptic special-
izations of inhibitory synapses.
What are the potential roles of synArfGEF at inhibitory
synapses? The Arf family comprises six structurally related
members that regulate membrane trafﬁcking and the actin
cytoskeleton (D’Souza-Schorey and Chavrier 2006). Of the
six Arf members, Arf6 is localized at the plasma membrane
and endosomes, and regulates the endosome-plasma mem-
brane trafﬁc and remodeling of the actin cytoskeleton at the
cell surface. At synapses, the submembrane cytoskeleton is
known to regulate the number and dynamics of neurotrans-
mitter receptors on the post-synaptic membrane, thereby
modulating synaptic efﬁcacy. At inhibitory synapses, both
Table 1 BRAG/IQSEC family proteins and interactors and key roles in synaptic function
Gene symbol and
chromosomol location
Other
names
GTPase
specificity Interacting proteins/proposed biological function References
IQSEC1 3p25.2 (human)
Iqsec1 6qDl (mouse)
GEP 100
BRAG2
IQSEC1
KIAA0763
p100
Arf1, Arf5, Arf6 • BRAG2 activating of Arf6 regulates endocytosis
and recycling of b1 integrins
• Alpha-catenin binding to ArfGEP100 activates
Arf6, resulting in E-cadherin recycling and actin
re-modelling
• BRAG2 interacts with a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA) receptor
subunit GIuA2 and activates Arf6, thereby
internalizing synaptic AMPA receptors upon
LTD induction
Dunphy et al. (2006)
Hiroi et al. (2006)
Scholz et al. (2010)
IQSEC2 Xp11.22 (human)
Iqsec2 XqF3 (mouse)
IQ-ArfGEF
BRAG1
IQSEC2
K1AA0522
Arf1, Arf6 • IQ-ArfGEF selectively activates Arf6 and forms a
complex with NDMA receptors via interactions with
PSD95 at excitatory synapses
• IQ-ArfGEF interacts with insulin receptor tyrosine
kinase substrate p53 (lRSp53) at excitatory PSDs
via its C-terminal proline-rich sequence
• IQ-ArfGEF mRNA is dendritically localized
• IQ-ArfGEF/BRAG1 localizes as retinal synaptic
ribbons and forms a protein complex with RIBEYE
• Missense mutations in IQSEC2 cause non-
syndromic X-linked intellectual disability
Murphy et al. (2006)
Dosemeci et al. (2007)
Sanda et al. (2009)
Katsumata et al. (2009)
Shoubridge et al. (2010)
IQSEC3 l2pl3.33 (human)
Iqsec3 6qF1 (mouse)
SynArfGEF
BRAG3
IQSEC3
KIAA1110
Arf1, Arf6 • SynArfGEF is able to interact with PSD-95, SAP97
and Homer/Vesll/PSD-Zip45 via a C-terminal
PDZ-binding motif
• SynArfGEF mRNA is dendritically localized
• SynArfGEF selectively activates Arf6 and interacts
with scaffolding proteins utrophin/dystrophin and
S-SCAM/MAGI-2 at inhibitory synapses
Inaba et al. (2004)
Hattori et al. (2007)
This study
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actin and microtubules have been shown to regulate the
lateral diffusion and stabilization of glycine receptors and
gephyrin (Charrier et al. 2006). In addition, gephyrin inter-
acts with various regulatory proteins for the cytoskeleton,
including polymerized tubulin (Kirsch et al. 1991), proﬁlin
(Mammoto et al. 1998) and mammalian enabled/vasodilator
stimulated phosphoprotein (Giesemann et al. 2003). In turn,
gephyrin depends on both actin and microtubules for
synaptic apposition and scaffold formation (Kirsch and Betz
1995). It is therefore possible that synArfGEF may initiate
local remodeling of the synaptic submembrane actin cyto-
skeleton through the activation of Arf6, thereby modulating
the lateral diffusion and stabilization of neurotransmitter
receptors and gephyrin at inhibitory synapses.
Another noteworthy ﬁnding is that synArfGEF interacts
with utrophin/dystrophin and S-SCAM via a PY motif and
PDZ-binding motif in the C-terminal region, respectively.
The ability of synArfGEF to bind utrophin/dystrophin was
veriﬁed by both yeast two-hybrid and pull down assays.
Although we failed to detect dystrophin or utrophin in co-
immunoprecipitation assays, b-dystroglycan and S-SCAM
were immunoprecipitated from brain lysates by the anti-
synArfGEF IgG. Consistent with previous ﬁndings demon-
strating that dystrophin and S-SCAM are localized to
inhibitory synapses (Knuesel et al. 1999; Sumita et al.
2007), immunostaining showed the colocalization of syn-
ArfGEF with dystrophin and S-SCAM. However, the anti-
utrophin antibody raised in this study did not result in any
immunolabeling in the cultured hippocampal neurons. This
is consistent with previous ﬁndings suggesting that utrophin
transcripts are predominantly expressed in endothelial cells
of blood vessels rather than in neurons (Knuesel et al.
2000). Hence, it is likely that S-SCAM and dystrophin, but
not utrophin, are physiological binding partners for synA-
rfGEF. At inhibitory synapses, dystrophin forms the DGC
with a- and b-dystroglycan, syntrophin, and a- and b-
dystrobrevin. Intriguingly, S-SCAM was shown to interact
directly with two inhibitory post-synaptic components, b-
dystroglycan and neuroligin-2 (Sumita et al. 2007). Thus,
the interaction of synArfGEF with dystrophin and S-SCAM
enables synArfGEF to activate Arf6 in the proximity of the
DGC and neuroligin-2 at inhibitory post-synaptic special-
izations. Mdx mice lacking a long form of dystrophin
exhibit a marked reduction in the clustering of GABAARs
containing the a2 subunit but retain gephyrin clustering in
the cerebellar cortex, suggesting a dystrophin-dependent and
gephyrin-independent mechanism for the clustering of
selected GABAAR subtypes. In the future, it will be of
particular interest to examine the possibility that synArfGEF
is involved in the dystrophin-dependent clustering of
GABAARs through Arf6-dependent actin cytoskeleton
remodeling.
Finally, it should be noted that the interaction of
synArfGEF with dystrophin and S-SCAM cannot account
for the speciﬁc mechanism for the targeting of synArfGEF to
inhibitory synapses, because dystrophin and S-SCAM are
only present at a subset of inhibitory synapses and S-SCAM
is present at both excitatory and inhibitory synapses (Knuesel
et al. 1999; Levi et al. 2002; Sumita et al. 2007). Therefore,
additional factors are required for speciﬁc targeting of
synArfGEF to inhibitory synapses.
In conclusion, we have demonstrated that synArfGEF
activates Arf6 and localizes preferentially at inhibitory post-
synaptic specializations, forming a protein complex with the
DGC and S-SCAM using distinct binding motifs. These
ﬁndings link Arf6 signaling pathways to inhibitory synapses
and suggest that synArfGEF may inﬂuence dynamic pro-
cesses affecting the synaptic localization of inhibitory
GABAA and glycine receptors.
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